Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
Executive Summary
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients
You may also be interested in...
Angiotensin Blockers Move To First-Line In ACC/AHA Heart Failure Guidelines
Angiotensin receptor blockers can be considered as a first-line treatment in heart failure patients with reduced left ventricular ejection fraction, the updated American College of Cardiology/American Heart Association heart failure guidelines indicate
Angiotensin Blockers Move To First-Line In ACC/AHA Heart Failure Guidelines
Angiotensin receptor blockers can be considered as a first-line treatment in heart failure patients with reduced left ventricular ejection fraction, the updated American College of Cardiology/American Heart Association heart failure guidelines indicate
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)